8-K: Mereo BioPharma Setrusumab Misses Primary Endpoints in OI Trials

Mereo BioPharma announced that its Phase 3 ORBIT and COSMIC studies for setrusumab in osteogenesis imperfecta did not meet primary endpoints for fracture rate reduction, despite showing significant improvements in bone mineral density.

Summary

• Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in osteogenesis imperfecta (OI) did not achieve statistical significance for their primary endpoints of reducing annualized clinical fracture rates.
• The ORBIT study failed to show a significant reduction in fracture rate compared to placebo.
• The COSMIC study failed to show a significant reduction in fracture rate compared to bisphosphonates.
• Both studies successfully met their secondary endpoints, demonstrating statistically significant and substantial improvements in bone mineral density (BMD) against comparators (placebo and bisphosphonates).
• No changes in the safety profile of setrusumab were observed across both studies.
• The company will conduct additional analyses on the data to determine the future path for the program, particularly for pediatric patients.
• Mereo BioPharma is implementing immediate reductions in pre-commercial and manufacturing activities for setrusumab and tightly controlling costs.
• The company's cash balance was $48.7 million at the end of the third quarter of 2025.

Sentiment

Score: 3

Explanation: The failure of setrusumab to meet primary endpoints in two Phase 3 studies for a rare disease with no approved treatments is a significant setback. While secondary endpoints for BMD were met, the lack of fracture rate reduction is a major negative. The company's immediate cost-cutting measures and focus on partnering other assets reflect the severity of this outcome, impacting future revenue potential from this key pipeline candidate.

Positives

• Setrusumab demonstrated statistically significant and substantial improvements in bone mineral density (BMD) in both ORBIT and COSMIC studies, consistent with Phase 2 results.
• No change in the safety profile of setrusumab was observed.
• In the pediatric COSMIC study, meaningful improvements in BMD were associated with a reduction in annualized fracture rate for setrusumab treated patients over bisphosphonate treated patients, even though it did not meet statistical significance.
• Mereo continues to advance partnering discussions for alvelestat and has existing partnerships for vantictumab and leflutrozole.

Negatives

• Neither the Phase 3 ORBIT nor COSMIC study achieved statistical significance for their primary endpoints of reduction in annualized clinical fracture rate.
• The ORBIT study's BMD improvements were not accompanied by a corresponding reduction in fracture rates, partly due to a low fracture rate in the placebo group.
• The reduction in annualized fracture rate in the COSMIC study, while associated with BMD improvements, did not meet statistical significance.
• The company is disappointed by the results and is implementing immediate reductions in pre-commercial and manufacturing activities for setrusumab.

Risks

• Uncertainties inherent in the clinical development process.
• Reliance on third parties to conduct and provide funding for clinical trials.
• Dependence on enrollment of patients in clinical trials.
• Dependence on key executives.
• Actual results could differ materially from current expectations due to known and unknown risks and uncertainties.

Future Outlook

Mereo BioPharma will conduct additional analyses on the setrusumab data to determine the best path forward for the program, especially in pediatrics. The company plans to tightly control costs, including immediate reductions in pre-commercial and manufacturing activities for setrusumab, and continue to advance partnering discussions for alvelestat and maximize value in its other owned and partnered programs.

Management Comments

• "Whilst we are disappointed by these results, we will be conducting additional analyses on the data, to assess next steps and the best path forward for the program, especially in pediatrics given the totality of the data and lack of other treatment options for individuals with OI."
• "In the meantime, we are carefully managing our cash resources with immediate reductions in our pre-commercial and manufacturing activities, and we are continuing to advance partnering discussions for alvelestat."

Industry Context

Osteogenesis Imperfecta (OI) is a group of genetic disorders impacting bone metabolism with no globally approved treatments, affecting approximately 60,000 people in commercially accessible geographies. Setrusumab, a sclerostin inhibitor, aimed to address this unmet need by increasing new bone formation and bone strength. The failure to meet primary fracture reduction endpoints, despite BMD improvements, highlights the challenges in developing effective treatments for complex rare bone diseases and the high bar for clinical success in this area. The lack of other treatment options for OI underscores the continued need for therapeutic innovation.

Comparison to Industry Standards

• The filing states that "No treatments are globally approved for OI," indicating a significant unmet medical need and a high potential market if successful.
• The observed BMD improvements were consistent with previous Phase 2 studies, suggesting the drug mechanism is active, but the disconnect with fracture rate reduction is a critical hurdle.
• The low fracture rate in the placebo group of the ORBIT study complicated the ability to show statistical significance, a common challenge in clinical trials for conditions with variable or lower event rates.
• The comparison to bisphosphonates in the COSMIC study is relevant as bisphosphonates are sometimes used off-label for OI, but setrusumab did not show statistically significant superiority in fracture reduction.

Stakeholder Impact

• Shareholders: Likely negative impact due to the failure of a key pipeline asset, potential for share price decline, and increased uncertainty regarding future revenue streams.
• Patients (OI): Disappointment as a promising potential treatment failed to demonstrate the desired clinical benefit in fracture reduction, leaving a significant unmet medical need.
• Employees: Potential for restructuring or workforce adjustments due to cost-cutting measures related to setrusumab's pre-commercial and manufacturing activities.
• Partners (Ultragenyx): Impact on their development plans and potential milestone payments related to setrusumab.

Next Steps

• Conduct additional analyses on the setrusumab data across both studies, including other bone health and clinical endpoints beyond fractures.
• Assess next steps and the best path forward for the setrusumab program, especially in pediatrics.
• Implement immediate reductions in pre-commercial and manufacturing activities for setrusumab.
• Tightly control costs.
• Continue to advance partnering discussions for alvelestat.
• Seek to maximize value in its owned and partnered programs.

Key Dates

Recommendation

The failure of setrusumab, a key pipeline asset, to meet its primary endpoints in two Phase 3 studies is a significant negative catalyst. While bone mineral density improvements were observed, the lack of statistically significant fracture rate reduction undermines the drug's commercial viability for its intended purpose. The company's immediate cost-cutting and focus on partnering other assets indicate a material impact on its financial outlook and future growth prospects. Given the high-risk nature of clinical-stage biopharma and this major setback, a 'sell' recommendation is warranted as the investment thesis for setrusumab has been severely weakened, leading to anticipated downward pressure on the stock price.

Keywords

Mereo BioPharma, MREO, Setrusumab, UX143, Osteogenesis Imperfecta, OI, Phase 3, Clinical Trials, Fracture Rate, Bone Mineral Density, Biopharma, Rare Diseases, Clinical Development, Drug Development